Results 91 to 100 of about 422,013 (303)

Treatment patterns and outcomes following disease progression on anti-PD-1 therapies for advanced melanoma

, 2022
Background: Anti-PD-1-based therapies prolong survival in advanced melanoma, but disease progression is common. This study evaluated treatment patterns and overall survival (OS) after anti-PD-1 progression.
Srivastava, Shivani, Nordstrom, Beth L, Collins, Jenna M, Earle, Dennis, Collins, Jenna M., Zhang, Ying, Hamilton, Melissa, Nordstrom, Beth L., Hernandez-Aya, Leonel   +8 more
core   +2 more sources

Stereotactic body radiotherapy for oligoprogression with or without switch of systemic therapy

Clinical and Translational Radiation Oncology
Background: Oligoprogression is defined as cancer progression of a limited number of metastases under active systemic therapy. The role of metastasis-directed therapy, using stereotactic body radiotherapy (SBRT), is controversial as is the continuation ...
Jonas Willmann, Eugenia Vlaskou Badra, Selma Adilovic, Maiwand Ahmadsei, Sebastian M. Christ, Stephanie Tanadini-Lang, Michael Mayinger, Matthias Guckenberger, Nicolaus Andratschke   +8 more
doaj   +1 more source

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

Roles of microRNAs during glioma tumorigenesis and progression [PDF]

, 2019
Glioma is the most common and aggressive type of brain tumor. It has a poor prognosis and a high recurrence rate. Despite continued advances in surgery, chemotherapy and radiotherapy, the clinical outcomes remain dismal.
Yin, Yutong, Wang, Shuwei, Liu, Shuang
core  

CASE REPORT DELAYED PROGRESSION AND INEFFICIENT TRANSMISSION OF HIV-2 [PDF]

, 2020
. We report a case of HIV-2 infection with delayed progression, taking approximately one and a half decades to develop HIV related symptoms. The spouse was still negative for HIV with a history of having regular unprotected sex with the index case which ...
Bineeta Kashyap, Hitender Gautam, Preena Bhalla, Sanjim Chadha   +3 more
core  

Effectiveness of Acceptance and Commitment Therapy Management on Self-Differentiation and Fear of Disease Progression in Patients with Breast Cancer

Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, 2020
BACKGROUND AND OBJECTIVE: Fear of disease progression and rejection of what happened and not being able to distinguish oneself from mental processes cause confusion in mental health.
M Hasannezhad Reskati, SH Hosseini, R Alizadeh-Navaei, S Khosravi, B Mirzaian   +4 more
doaj  

Combination treatment with nivolumab and Rigvir of a progressive stage IIC skin melanoma patient

Clinical Case Reports, 2019
A 35‐year‐old male patient was diagnosed with stage IIC skin melanoma that rapidly progressed after surgery. Treatment was continued with radiotherapy, which did not stop further spread of disease and the patient was put on a combination of nivolumab and
Linda Brokāne, Inta Jaunalksne, Andra Tilgase, Evija Olmane, Donatas Petroška, Agnija Rasa, Pēteris Alberts   +6 more
doaj   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Early discontinuation of immune checkpoint inhibitor therapy prior to disease progression in patients with metastatic non-small cell lung cancer: a survival analysis

Frontiers in Oncology
IntroductionLimited survival data are available for patients with metastatic non-small cell lung cancer (mNSCLC) who stop immune checkpoint inhibitor therapy (ICI) early for reasons other than progression of disease (POD), such as immune-related adverse ...
Blake J. McKinley, Tanmayi S. Pai, Emily B. Wolf, Shenduo Li, Guilherme Sacchi de Camargo Correia, Yujie Zhao, Rami Manochakian, Yanyan Lou   +7 more
doaj   +1 more source

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source